Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care

Posted on October 17, 2022 by -

Pierone G, Brunet L, Fusco JS, et al. Switching to dolutegravir/lamivudine two-drug regimen: durability and virologic outcomes in routine U.S. clinical care. Presented at: 24th International AIDS Conference 2022; Montreal, Canada

<Download PDF>